Drug intelligence / Profile preview

TK-254RX

Development stage
Unknown
Lead developer
Teikoku Pharma USA
Modality
Small Molecules
Administration
Topical
01

Overview

TK-254RX is an investigational topical hydrogel patch containing 1.5% esflurbiprofen (the S-enantiomer of flurbiprofen), developed by Teikoku Seiyaku Co., Ltd. for the treatment of acute pain and soft tissue injuries such as contusions, sprains, and strains. The patch utilizes proprietary Hydrohesive® technology, a hydrophilic adhesive formulation designed for once-daily application. As a nonsteroidal anti-inflammatory drug (NSAID), esflurbiprofen acts by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the production of prostaglandins that mediate pain and inflammation. This topical delivery system is intended to provide localized relief with lower systemic exposure compared to oral NSAIDs, potentially reducing the risk of gastrointestinal and cardiovascular side effects.

Other names
esflurbiprofen patchS-flurbiprofen patchesflurbiprofen 1.5% hydrogel patch
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on TK-254RX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TK-254RX.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call